



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: **C12P 19/34, C12M 1/34** (11) International Publication Number: **A1** (43) International Publication Date: **16 November 2000 (16.11.2000)** **WO 00/68410**

(21) International Application Number: **PCT/US00/12822** Published
(22) International Filing Date: **08 May 2000 (08.05.2000)**

(30) Priority Data:
60/133,168 07 May 1999 (07.05.1999) US

(60) Parent Application or Grant
VISIBLE GENETICS INC. [], () YAGER, Thomas, D []; () AUGUST, M., Jason [], () YAGER, Thomas, D. []; () AUGUST, M., Jason [], () LARSON, Marina, T [], ()

(54) Title: NUCLEIC ACID SEQUENCING WITH SIMULTANEOUS QUANTITATION
(54) Titre: SEQUENÇAGE D'ACIDE NUCLEIQUE A QUANTIFICATION SIMULTANEE

(57) Abstract

Simultaneous sequencing and quantitation of a nucleic acid analyte in a sample using the same reagents for both assays is achieved by processing a sample containing, or suspected of containing the nucleic acid analyte of interest using a single set of reagents through a plurality of thermocycles to obtain a mixture of labeled polynucleotides which are used for the determination of both sequence information about the target nucleic acid and the amount of target nucleic acid present in the sample. The fragments are separated on the basis of size, for example by electrophoresis, and the label associated with the separated fragments is detected. The positions of the separated nucleic acid fragments are evaluated to obtain information about the sequence of the target nucleic acid analyte, and the intensity of a signal derived from the label associated with one or more of the separated fragments is evaluated to determine the quantity of the target nucleic acid analyte in the sample. Only one label is needed for both sequencing and quantitation, although two or more labels may be used if bidirectional sequencing is concurrently performed.

(57) Abrégé

Le séquençage et la quantification d'un analyte d'acide nucléique dans un échantillon, au moyen des mêmes réactifs pour les deux essais, s'effectuent par le traitement d'un échantillon contenant un analyte d'acide nucléique, ou suspecté d'en contenir, au moyen d'un seul ensemble de réactifs, sur plusieurs thermocycles, de manière que soit produit un mélange de polynucléotides marqués utilisés pour la détermination à la fois des informations séquentielles relatives à l'acide nucléique cible et de la quantité d'acide nucléique présente dans l'échantillon. Les fragments sont séparés par taille, par exemple par électrophorèse, et le marqueur associé aux fragments séparés est détecté. Les positions des fragments d'acide nucléique séparés sont évaluées, de manière que des informations relatives à la séquence de l'analyte d'acide nucléique cible soient obtenues, et l'intensité d'un signal dérivé du marqueur associé à un ou plusieurs des fragments séparés est évaluée, de manière que la quantité d'analyte d'acide nucléique cible dans l'échantillon soit déterminée. Seul un marqueur est nécessaire pour le séquençage et la quantification, bien que deux marqueurs ou plus puissent être utilisés si un séquençage bidirectionnel est mené à bien simultanément.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12P 19/34, C12M 1/34		A1	(11) International Publication Number: WO 00/68410
			(43) International Publication Date: 16 November 2000 (16.11.00)
<p>(21) International Application Number: PCT/US00/12822 (22) International Filing Date: 8 May 2000 (08.05.00)</p> <p>(30) Priority Data: 60/153,168 7 May 1999 (07.05.99) US</p> <p>(71) Applicant (for all designated States except US): VISIBLE GENETICS INC. (CA/CA); 700 Bay Street, Toronto, Ontario M5G 1Z6 (CA).</p> <p>(72) Inventors; and (73) Inventors/Applicants (for US only): YAGER, Thomas, D. [US/CA]; 1879 Silverberry Crescent, Mississauga, Ontario L5J 1C8 (CA). AUGUST, M., Jason [CA/CA]; 164 Randolph Road, Toronto, Ontario M4G 3S4 (CA).</p> <p>(74) Agents: LARSON, Marina, T. et al.; Oppedahl & Larson LLP, P.O. Box 5068, Dillon, CO 80435-5068 (US).</p>			<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: NUCLEIC ACID SEQUENCING WITH SIMULTANEOUS QUANTITATION

(57) Abstract

Simultaneous sequencing and quantitation of a nucleic acid analyte in a sample using the same reagents for both assays is achieved by processing a sample containing, or suspected of containing the nucleic acid analyte of interest using a single set of reagents through a plurality of thermocycles to obtain a mixture of labeled polynucleotides which are used for the determination of both sequence information about the target nucleic acid and the amount of target nucleic acid present in the sample. The fragments are separated on the basis of size, for example by electrophoresis, and the label associated with the separated fragments is detected. The positions of the separated nucleic acid fragments are evaluated to obtain information about the sequence of the target nucleic acid analyte, and the intensity of a signal derived from the label associated with one or more of the separated fragments is evaluated to determine the quantity of the target nucleic acid analyte in the sample. Only one label is needed for both sequencing and quantitation, although two or more labels may be used if bidirectional sequencing is concurrently performed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mal	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

5

NUCLEIC ACID SEQUENCING WITH SIMULTANEOUS QUANTITATION

10

Field of the Invention

This application relates to a method and kit for the simultaneous sequencing and quantitation of a nucleic acid analyte in a sample.

15

5 Background of the Invention

Academic and commercial interest in nucleic acid diagnostics has, to date, focused on qualitative assays. This type of assay determines the presence or absence in a patient sample of a specific gene mutation or infectious pathogen. Molecular assays which achieve these goals are well known. Many rely on amplification techniques, known to those skilled in the art such as the polymerase chain reaction (PCR), NASBA or 3SR, with or without hybridization probing. Others such as Digene Hybrid Capture Assays (DiGene Diagnostics Inc.) do not require amplification prior to detection and are generally less sensitive. Assays have been developed for many infectious pathogens such as *Chlamydia trachomatis*, Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2), and human papilloma virus (HPV). Some of these tests have been launched commercially by Roche Diagnostic Systems, Abbott Laboratories and others.

20

Quantitative assays of nucleic acid analytes also prove useful in diagnosis of a variety of medical disorders. For example, viral load in HIV infection may be correlated with increased risk of clinical progression of HIV disease (Mellors, J. W. et al. (1995).

25

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122: 573-579) While this example is best known, other quantitative applications also have clinical and commercial interest, such as quantitation of human papilloma virus in PAP smears. (Cuzick, J. et al. (1994) Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br. J. Cancer 69:167-171; Bavin P.J. et al. (1993) Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report. Br. J. Cancer 67:602-605.)).

30

35

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann.

40

Intern. Med. 122: 573-579) While this example is best known, other quantitative applications also have clinical and commercial interest, such as quantitation of human papilloma virus in PAP smears. (Cuzick, J. et al. (1994) Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical

45

intraepithelial neoplasia. Br. J. Cancer 69:167-171; Bavin P.J. et al. (1993) Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report. Br. J. Cancer 67:602-605.)).

50

55

5

- 2 -

10

Notwithstanding their usefulness, quantitative assays of nucleic acid analytes have lagged behind in development. The delay may in part be attributed to technology barriers. Most instruments and methods provide inadequate dynamic range for measuring quantities, thus requiring labor intensive techniques such as multiple serial dilutions and repeat reactions. Further, until recently, PCR methods have been perceived as unreliable for quantitation due to the possibility of contamination and non-linear enzyme kinetics.

15

20

The AMPLICOR HIV-1 MONITOR® (Roche Molecular Systems) test is a quantitative molecular assay for HIV RNA levels in blood. The assay is performed on HIV-1 and a subset of HIV-2 RNA found in 200 μ L of blood plasma. The RNA is purified from the plasma sample, reverse transcribed and amplified by PCR. The reaction products are quantified by a probe based photometric assay and compared to the levels of a control RNA of known quantity that is added to the plasma sample. The control RNA is reverse transcribed along with the sample RNA and co-amplified using the same amplification primers. Six serial dilutions are necessary to detect across the full range of detectable viral load: 400 copies to 750,000 copies per mL. The test requires that for samples over 750,000 copies, (over 2.2 million copies per mL have been detected) the original patient sample must be diluted. The AMPLICOR assay therefore quantifies across the full range of possible values by a series of multiple dilutions. The AMPLICOR assay does not determine which sub-type or sub-types of HIV-1 are present, and it does not establish if HIV-2 was amplified.

25

30

35

40

Other quantitative HIV assays have been reported. Some of these papers, incorporated herein by reference, include:

45

Mulder, J et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J. Clin. Micro. 32:292-300

50

Dewar, R.L. et al, 1994 Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. Infect. Dis. 170:1172-1179

55

5

- 3 -

10

van Gemen, B. et al. 1993. Quantitation of HIV-1-1 RNA in plasma using NASBA during HIV-1-1 primary infection. J. Vir. Meth. 43:177-188.

15

Each of these prior methods would require the performance of a separate set of reactions for quantitation and sequencing, and even if these methods could be performed concurrently in a single vessel the need for multiple reaction increases the number of reagents required and thus the cost of the procedure.

20

WO98/41650 discloses a method for quantitative and qualitative analysis of a nucleic acid analyte in a sample suspected to contain the nucleic acid analyte. The method comprises the steps of:

25

(a) combining the sample with a control nucleic acid, and two primer pairs, a first primer pair effective to amplify a conserved region of the nucleic acid analyte if present in the sample to produce a conserved fragment having a first length and to amplify the control nucleic acid to produce a control fragment having a second length different from the first length, one member of the first primer pair being labeled with a detectable label, and

30

a second primer pair effective to amplify a second region of the nucleic acid analyte to produce a sequencing fragment, one member of the second primer pair being labeled with a label effective to permit capture of the primer;

35

(b) amplifying the sample and control nucleic acid using the first and second primer pairs to produce an amplification product mixture containing conserved fragments, sequencing fragments and control fragments when the nucleic acid analyte is present in the sample, and only control fragment when the nucleic acid analyte is not present in the sample;

40

(c) analyzing the relative amounts of conserved fragments and control fragments in the amplification product mixture to quantify the amount of nucleic acid analyte in the sample; and

45

(d) determining the sequence of the sequencing fragment in the amplification mixture to determine the qualitative characteristics of any nucleic acid analyte in the sample. Thus, although the methodology of WO98/41650 permits sequencing and

50

55

5

- 4 -

quantitation in a common reaction, it utilizes different primer pairs for the generation of products evaluated for sequencing and quantitation.

10

Summary of the Invention

The present invention provides a methodology and associated kits for simultaneous sequencing and quantitation of a nucleic acid analyte in a sample using the same reagents for both assays. In accordance with the invention, a sample containing, or suspected of containing the nucleic acid analyte of interest is processed using a single set of reagents through a plurality of thermocycles to obtain a mixture of labeled polynucleotides which are used for the determination of both sequence information about the target nucleic acid and the amount of target nucleic acid present in the sample. The fragments are separated on the basis of size, for example by electrophoresis, and the label associated with the separated fragments is detected. The positions of the separated nucleic acid fragments are evaluated to obtain information about the sequence of the target nucleic acid analyte, and the intensity of a signal derived from the label associated with one or more of the separated fragments is evaluated to determine the quantity of the target nucleic acid analyte in the sample. In accordance with the invention, only one label is needed for both sequencing and quantitation, although two or more labels may be used if bidirectional sequencing is concurrently performed.

20

35

Brief Description of the Drawings

Fig. 1 is a calibration plot for the determination of the efficiency of PCR, E_2 ;

Fig. 2 is a calibration plot for the determination of the efficiency of CLIP, E_3 ;

Fig. 3 is a calibration plot for the determination of the efficiency of reverse transcription (RT), E_1 ;

Fig. 4 is a set of curves describing the overall efficiency of an RT-PCR process;

Figs 5A and 5B show the relationship between signal intensity and number of CLIP cycles for the full length peak and sequencing fragment peaks, respectively;

Fig. 6 shows primer positions for a three-dye scheme for analysis of a test sequence using an internal standard;

40

55

5

- 5 -

Figs. 7A-D show raw data traces obtained for aliquots taken after varying numbers of CLIP cycles;

10

Fig 8 shows normalized signal intensity as a function of cycle number;

5

Fig. 9 illustrates the relationship between signal intensity and cycle number in the early phase of the CLIP reaction; and

15

Fig. 10 illustrates the relationship between signal intensity and cycle number in the later phase of the CLIP reaction.

Detailed Description of the Invention

20

10 The present application can be utilized in the analysis of either DNA or RNA analytes, and is particularly useful for the simultaneous determination of microbial (bacterial or viral) type and load. As discussed below, one particular application for the invention is in the simultaneous genotyping and viral load determination for HIV-1.

15 In accordance with the invention, a sample containing or suspected of containing a target nucleic acid is processed using a single set of reagents to produce labeled polynucleotides which are used for the determination of both sequence information about the target nucleic acid and the amount of target nucleic acid present in the sample. As used herein, the phrase "a single set of reagents" means that the same reagents are used to produce the fragments of nucleic acid that are used to convey information about both the 20 amount and sequence of the target nucleic acid. It does not preclude the use of multiple sets of primers in different steps to generate these fragments (for example nested PCR and sequencing fragments) nor does it preclude the use of a different set of primers for the creation of fragments from an internal standard sequence or a calibration sequence. 25 The use of a single set of reagents also encompasses the use of this same set of reagents in each of two or more parallel replicate reactions conducted in different vessels.

30 The invention can be practiced in several variations. First, the invention may be practiced such that the same fragments (i.e., sequencing fragments) are evaluated for both determinations. Second the invention may be practiced such that different fragments or groups of fragments produced by reaction with the single set of reagents are used for the 35 two determinations, for example, sequencing fragments for the determination of sequence information and a full-length peak (from coupled amplification and sequencing 40

30

45

50

55

5

- 6 -

10

or CLIP) for the determination of the amount of target nucleic acid. Within this second alternative there are further variations. The different fragments or groups of fragments may be produced in parallel replicate reactions with the same reagents in each tube, or they may be produced in a single tube. Furthermore, while the fragments used to determine the sequence information and the amount of target nucleic acid are all generated as a result of the a single set of reagents, it is not required that they have been subjected to the same number of thermal cycles. Thus, in the first case, the number of thermal cycles used in the creation of the fragments may be different between the two tubes. In the second case, an aliquot may be removed from the reaction mixture for use in the determination of the amount of target nucleic acid at an intermediate stage of the reaction, with additional thermal cycles being performed subsequently to produce fragments for determination of sequence information.

15

20

25

10

Besides these variations, the method of the invention may include additional steps, depending on the nature of the sample and on the nature of the chemistry employed to produce the polynucleotide fragments. Thus, in accordance with one embodiment of the invention, the sample is first processed through one or more steps which increase the amount of target nucleic acid present in the sample. By way of example, an RNA sample (for example an HIV-1 RNA from a human AIDS patient) is subjected to an RT-PCR procedure, in which reverse transcription is used to make a 1st strand cDNA copy of the RNA, and the cDNA copy is then amplified by PCR. DNA samples, on the other hand, could be amplified directly by PCR, or other amplification techniques, including LCR (ligase chain reaction) and the like.

30

35

20

After the increase in the amount of the DNA, the DNA is processed to generate Sanger-type sequencing fragments, incorporating a detectable label, using a single set of reagents. A preferred label type is a fluorescent label, although radiolabels, chromophoric labels, or chromogenic or fluorogenic labels can also be used. The method for producing the sequencing fragments may be cycle sequencing as described in Kretz et al., in *PCR Methods and Applications* 3: S107-S112 (1994) or coupled amplification and sequencing (CAS) as described in US Patent No. 5,427,911 which are incorporated herein by reference. These processes produce fragments which can be analyzed to determine both the amount of target nucleic acid and sequence information

40

25

45

30

50

55

5

- 7 -

10

about the target nucleic acid. In the case of cycle sequencing, a full-length product may not be generated in sufficient amount for quantitation. Thus, if cycle sequencing is used to generate the fragments, the sequencing peaks are used directly for determination of the amount of the target nucleic acid in the sample.

15

5 The prior step of increasing the amount of nucleic acid in the sample is not necessary, however, since it is possible to generate fragments in a single step process using a single set of reagents. Such a process is described in US Patents Nos. 5,830,657 and 5,888,736, which are incorporated herein by reference, and is referred to herein by the assignee's trademark for this procedure, CLIP. This type of reaction can be used 10 independently (in which case it plays the part of both types of steps) or in combination with a distinct step for increasing the amount of nucleic acid analyte in the sample. In the CLIP reaction, the sample is combined with forward and reverse primers flanking the 15 region of interest, a thermally stable polymerase with low discrimination between deoxy and dideoxynucleoside triphosphates, deoxynucleoside triphosphates and one species of dideoxynucleoside triphosphate. This reaction mixture is cycled through multiple 20 thermocycles to create fragments terminated with the dideoxy nucleoside.

25

25 An important characteristic of the processing step or steps used to generate the polynucleotide fragments is that they be performed in the "quantitative regime." It is known in the art that cyclic processes may decrease in efficiency after a number of 30 cycles, such that the amount of product from one cycle to the next ceases to be directly related in a simple and predictable fashion to the amount of product in the preceding cycle. Thus, for example, in a PCR amplification, in the first cycle the amount of 35 product after the first cycle is essentially 2 times the amount of starting material, after the second cycle it is essentially 4 times, then 8 times and so forth. At some number of 40 cycles, however, the amount of product is less than would be predicted according to a simple exponential growth model. The present invention should be performed at lower 45 cycle numbers where this decrease in efficiency is not observed, and where a plot of log of the amount of product as a function of cycle number is linear. This is referred to in the specification and claims as being "within a quantitative regime."

50

30 In order to maintain the reaction within a quantitative regime, it may be desirable to take an aliquot of sample for determination of the amount of nucleic acid analyte, and

55

5

- 8 -

10

15

25

30

35

40

45

50

55

then continue for additional cycles of the reaction generating sequencing fragments to produce the final mixture that will be used in sequence analysis. For example, as discussed in greater detail below, it has been determined that in the CLIP reaction the product produced in the first 20 cycles is predominantly the full-length product, while in subsequent cycles (for example 25-40) the amount of full-length product has reached a plateau and the sequencing fragments increase in number. If the full length product is to be used for quantitation, it is desirable to take an aliquot after about 20 cycles for this purpose, and then continue for additional cycles to generate sequencing ladders.

After the fragments are generated, they are separated by size, for example by electrophoresis, and detected using an apparatus appropriate to the type of label. The intensity of the sequencing peaks may be evaluated as a measure of the amount of nucleic acid analyte in the sample. The "intensity" utilized may be based on any reproducible parameter which reflects the intensity of the signal from a given peak, such as the height or area of the peaks. The "intensity" may be determined based on a representative peak (such as the full length peak) or it may be determined based on an average or total of individual peak heights over a predetermined window. This intensity is correlated to the amount of nucleic acid which was produced in the sequencing reaction, which is in turn correlated to the amount of nucleic acid analyte which was present in the initial sample. Intensities of the full length peak and terminated sequencing fragment peak(s) can be used independently to provide confirmatory measures of the amount of target nucleic acid in the sample.

The sequencing fragments in the modified sample are also used for the determination of information about the sequence of the target nucleic acid analyte in accordance with techniques well-known in the art. Thus, the present invention provides a method for the simultaneous sequencing and quantitation of a target nucleic acid analyte in a sample using a single set of reagents, optionally in a single vessel.

The method of the invention is suitably practiced using a kit which is specifically adapted for use in the method. For a given target nucleic acid, the kit may contain at least a primer pair flanking a region of analytical interest within the target nucleic acid, a thermostable template-dependent DNA polymerase, feedstock solutions and buffers for performing a thermally-cycled primer extension reaction, and calibration information

5

- 9 -

10

specific to the production lot of reagents within the kit. The calibration information may be in the form of numerical efficiency parameters or calibration curves provided in print on packaging or product inserts accompanying the kit. The calibration information may also be in machine-readable format, for example a diskette or compact disk.

15

5 Alternatively, the calibration information may be provided indirectly, by packaging with the kit the instructions (and a password/user code if desired) for obtaining calibration information from an on-line source such as an web site or an ftp site.

20

10 Additional components may be included in the kit to provide the complete chemistry for the method to be performed. Thus, for purposes of analyzing RNA targets, the kit also includes a reverse transcriptase and the corresponding calibration information. Where the methodology employed utilizes a separate amplification step, the kit includes appropriate reagents (such as PCR primers which flank the primers for generating the final sequencing fragments) and corresponding calibration information.

25

15 A kit for quantitation and sequencing of a target nucleic acid analyte with an internal standard does not need reagent-specific calibration information. In this case, the kit includes the reagent components listed above, plus a reference polynucleotide, which may be provided in pre-measured amounts, and primers (including at least one labeled primer) for carrying out coprocessing of the reference polynucleotide with the sample.

30

30 When a two step process involving PCR amplification followed by generation of 20 terminated sequencing fragments is employed, the reference polynucleotide and the sample are preferably amplified by the same primers to produce an amplification product of substantially equal length. In addition, although the primers for generation of 35 sequencing fragments are different, and are labeled with distinguishable labels, they 25 preferably produce full-length products of equal, or at least substantially equal length.

40

40 Selection of such primers is desirable to eliminate or minimize any differential 25 amplification that may arise from different template lengths. Also, the reference 45 polynucleotide preferably has a substantially similar composition and sequence to the target nucleic acid analyte, to eliminate or minimize any differential amplification that 50 may arise from differences in template composition or sequence.

55

30 In the following explanation the sequencing fragments are assumed to be generated in a CLIP reaction. It will, however, be appreciated that other types of

5

- 10 -

sequencing reactions could also be utilized, without departing from the invention.

10

Further, this discussion assumes an initial RNA sample and thus includes a discussion of RT efficiency which would of course be irrelevant to a DNA analyte. In addition, while the following discussion refers to the separate determination of efficiencies for each step of the reaction and the application of these efficiencies individually to the experimental peak size, an overall efficiency could also be determined and applied to the experimental peak size to arrive at a quantitation of the amount of nucleic acid analyte sequenced.

5

The following specific discussion and examples are provided to provide a more complete understanding of the invention, and are not intended as limitations on the scope 15

20

of the invention as described generally above

Example 1

25

The amount of an RNA target nucleic acid analyte in a sample can be determined from the intensity of a sequencing reaction peak or peaks as follows. The sample 15 contains an initial molar amount X_1 of the RNA target. By reverse transcription, this is converted into an molar amount X_2 of full-length first-strand cDNA. This conversion 30 process has an efficiency E_1 , where $0 \leq E_1 \leq 1$. Thus,

$$X_2 = E_1 X_1$$

35

The molar amount X_2 of the first-strand cDNA is passed into a PCR reaction for 20 cycles, each with an efficiency E_2 , where $0 \leq E_2 \leq 1$. The PCR is performed within a quantitative regime so that E_2 is constant across cycles. This produces a molar amount X_3 of double-stranded PCR product:

$$X_3 = X_2 (1 + E_2)^n$$

40

The molar amount X_3 of double-stranded PCR product is passed into a CLIP reaction for 25 cycles, each with an efficiency E_3 , where $0 \leq E_3 \leq 1$. Again, CLIP is performed in a quantitative regime so that E_3 is constant across cycles. This produces a molar amount 45 X_4 of CLIP product,

$$X_4 = X_3 (1 - E_3)^m$$

50

55

5

- 11 -

10

These equations are combined to obtain an expression which relates the amount of CLIP product (X_4 , a measured quantity) to the initial amount of RNA template present in the sample (X_1 , the unknown we would like to determine) as follows:

$$X_4 (E_1 X_1) (1+E_2)^n (1+E_3)^m.$$

10

This equation can be transformed to a logarithmic form:

$$\log(X_4) = \log(X_1 E_1) + n(\log(1+E_2)) + m(\log(1+E_3)).$$

15

The equations for X_4 and $\log(X_4)$ describe a monotonically-increasing function, $X_4 = f(X_1)$ with five parameters (E_1 , E_2 , E_3 , n and m). The number of PCR cycles (n) and the number of CLIP cycles (m) are fixed by the analyst performing the assay. Therefore, three calibration runs to establish E_1 , E_2 and E_3 should make these equations determinant.

20

The first calibration run is performed to determine the efficiency of the PCR reaction, E_2 . In this calibration, samples prepared after different numbers of PCR cycles (n) are processed with a fixed amount of DNA template and a fixed number of CLIP cycles to produce measured amounts of CLIP product. The results are plotted in a semilog plot of X_4 (CLIP product) versus n as shown in Fig. 1. The slope of the line is equal to $\log(1+E_2)$ which allows the determination of a value of E_2 .

25

The second calibration run is performed to determine the efficiency of the CLIP reaction, E_3 . In this calibration, samples prepared with a fixed amount of DNA template and a fixed number of PCR cycles are subjected to differing numbers of CLIP cycles to produce measured amounts of CLIP product. The results are plotted in a semilog plot of X_4 (CLIP product) versus m as shown in Fig. 2. The slope of the line is equal to $\log(1+E_3)$ which allows the determination of a value of E_3 .

30

To determine the efficiency E_1 of the RT reaction, we first rewrite the equation as follows:

$$\log(X_4) = k + \log(X_1) + \log(E_1)$$

40

where the constant $k = n(\log(1+E_2)) + m(\log(1+E_3))$. A third calibration experiment is done in which samples containing varying amounts of RNA template are processed for a fixed number of PCR cycles and a fixed number of CLIP cycles. A log-log plot of the measured amount of product (X_4) versus the known amount of RNA template (X_1) has a slope of 1 and an intercept equal to $k + \log(E_1)$ as shown in Fig. 3. Since k can be

45

50

55

5

- 12 -

calculated from the previous calibrations and known values, the value of E_1 can be determined from the intercept.

10

The three efficiency parameters, E_1 , E_2 and E_3 may be determined for each batch of reagents packaged into kit format. In this case, the efficiency parameters are supplied (in the form of a calibration sheet or other format for providing calibration information) with each kit containing reagents from a particular production run, and can be used to generate performance curves through the expiry date of the kit. Alternatively, the kit can contain all of the reagents and instructions for the user to perform and determine kit-specific efficiency parameters in accordance with the invention.

20

10

Example 2

As an alternative to the individual determination of the efficiency parameters, the overall efficiency of the conversion of starting template to product (sequencing fragments) may be considered. In this case, an empirical set of performance curves may be generated for each production run of reagents in a kit. These curves describe the overall efficiency of the sequencing and quantitation process under various operating conditions. An example is shown in Fig. 4. In this multidimensional plot, the x-axis is the amount of template (X_1), the y-axis is the number of CLIP cycles (m) and the z-axis is the measured amount of product (X_4). As can be seen, increasing amounts of template produce curves with an inflection point at decreasing numbers of CLIP cycles. Therefore, if the number of CLIP cycles (m) is known, the amount of template (X_1) can be inferred from the shape of the product intensity curve (X_4) versus CLIP cycles (m).

40

Example 3

25 A double stranded HIV-1 amplicon was subjected to quantitative CLIP, both in undiluted form and at a 1000-fold dilution. The undiluted sample produced a high intensity signal in both the full-length CLIP portion, and also in the CLIP sequencing ladder after CLIP cycle number 12. Over this number of cycles, the 1000X dilution produced a much less intense signal for both the full length product and the sequencing ladder. For the diluted sample, approximately 27 CLIP cycles were required to obtain the similar signal intensities.

55

5

- 13 -

10

There is a quantitative relationship between template concentration and intensity of the CLIP products. This can be seen clearly by graphing signal intensity as a function of CLIP cycle number. Fig. 5A shows such a plot for the full length peak observed for the undiluted and diluted samples described above. Fig. 5B shows a comparable plot for dideoxy-terminated peaks in a T-rich region at positions 204-252.

15

Example 4

20

The invention may also be configured to use an internal standard to achieve absolute calibration. The internal standard is coprocessed in the same reaction to produce polynucleotide sequencing fragments having a distinctive dye as a label. For example as illustrated in Fig. 6, two DNA templates which have identical PCR priming sites (P_1 and P_2) but different CLIP priming sites (P_3 and P_4 in the internal standard sequence, P_5 and P_6 in the test sequence) can be used. Preferably, the length $|P_2-P_3|$ should be the same in the two templates. Also, the length $|P_2-P_3|$ should equal the length $|P_6-P_5|$ to eliminate any differential amplification in PCR or CLIP that arises from different template lengths. The templates are simultaneously coamplified by PCR using primers P_1 and P_2 . Two independent, but simultaneous CLIP reactions are then performed in the same tube. One reaction produces sequencing fragments from the internal standard sequence using primers P_3 and P_4 . The other produces sequencing fragments from the test sequence using primers P_5 and P_6 . Also, the primers pairs (P_3/P_4 and P_5/P_6) preferably have comparable thermodynamic binding properties (Tm's) for their targets. Suitably, one of the primers for the internal standard sequence and both primers for the test sequence are labeled with distinctive labels, such as CY5, CY5.5 and CY7 as shown in order to achieve both quantitation and bidirectional sequencing of the target molecule in the same reaction. Since the amount of control sample added in the first instance is known, the intensity of the control peak (adjusted for differences in excitation efficiency and instrumental detection efficiency), provides an absolute calibration against which signal intensity of the peaks derived from the test sequence can be measured.

40

45

To demonstrate the sequence accuracy of performing two simultaneous CLIP reactions to obtain sequence information in a single tube, two templates and two sets of CLIP primers were combined. Template 1 was a 1274 bp HIV RT-PCR product

55

5

- 14 -

10

sequenced using an unlabeled forward primer and a CY5-labeled reverse primer. Template 2 was a 330 bp segment of HLA DRB1 gene, sequenced using an M13 CY5.5-labeled forward primer and an unlabeled reverse primer. The templates and primers were combined with AmpliTaq FS polymerase, terminating dideoxy-and non-terminating deoxynucleoside triphosphates and cycled through multiple thermal cycles (60°C annealing temperature). After the CLIP reaction, the reaction products were analyzed by electrophoresis on a Visible Genetics LONG READ TOWER™ instrument. Sequence analysis of the second template showed 100% match between template 2 and known comparators for human MHC gene HLA DRB1, thus confirming the capacity of the reaction to generate sequencing fragments for two independent species in the same tube

15

20

10

Example 5

25

In the CLIP reaction, a DNA template is combined with both chain terminating and normal dideoxynucleoside triphosphates and processed through multiple chain extension cycles. The reaction is biphasic, however, with an early phase in which extension to full length products is favored, and a later phase in which predominantly chain termination fragments are formed. To illustrate the biphasic nature of the CLIP reaction, a CLIP reaction was performed using a labeled forward primer and an unlabeled reverse primer and aliquots were taken at intervals. Figs. 7A-D show selected portions of raw data traces for aliquots of sample taken from the CLIP reaction after 8, 17, 26 and 35 cycles.

15

30

35

20

40

25

A similar experiment was performed using two labeled primers. Fig. 8 shows a plot of normalized signal intensity as a function of cycle number. The open symbols in Fig. 8 are representative of the full length product, while the closed symbols are representative of the chain-terminated sequencing fragments.

45

50

The above experiments clearly confirm the biphasic time-course of the CLIP reaction. Over the first ~20 cycles, the full-length product becomes visible, but very little sequence ladder (chain termination product) is observed. In contrast, over subsequent cycles, the amount of full-length product reaches a plateau and the quantity of dideoxy-terminated sequencing fragments begins to increase. This biphasic behavior can be exploited to simplify the simultaneous determination of the sequence and quantity of a

55

5

- 15 -

10

target polynucleotide using the same reagents by taking a measurement for quantitation during the early phase and performing the sequencing analysis on products from the later phase. This can be accomplished by preparing either a single sample or parallel replicate samples. An aliquot is taken out for quantitation after ~20-25 cycles and stored on ice.

15

The other (or remaining) sample is cycled for an additional number of cycles, and a second aliquot is collected after ~26-35 cycles for sequences analysis. The two aliquots are then run on adjacent lanes of a gel for simultaneous sequence determination and quantitation of the amount of the target nucleic acid.

20

10

Example 6

25

In order to use the CLIP reaction in the method of the invention, it was established that the amount of full-length product increases monotonically with (1) the number of reaction cycles and (2) the amount of template initially present. Only if these two conditions are met, can a meaningful calibration curve be constructed to permit determination of the amount of target nucleic acid in an unknown sample. Fig. 9 illustrates the relationship between signal intensity and cycle number in the early phase of the CLIP reaction. In this experiment, both the forward and reverse primer were labeled and the intensity of the peak associated with the full-length product was measured. Fig. 9 shows that the log of the signal intensity increases monotonically with the number of reaction cycles over a 3 to 4 order of magnitude dynamic range.

35

20

Fig. 10 shows a comparable plot to Fig. 9, but based on the intensity of sequencing fragment peaks obtained in the second phase of the CLIP reaction. Again, the signal intensity increases monotonically with number of cycles over a 3 order of magnitude dynamic range. Thus, in an assay performed without an internal standard, the quantitative result obtained from consideration of the intensity of the full length peak appearing during the early phase of the CLIP reaction can be confirmed by consideration of the intensity of the sequencing ladder peaks appearing during the later phase of the CLIP reaction.

50

55

5

- 16 -

Example 7

Template one (the test nucleic acid) is a sequence of HIV-1, M group, B subtype. Template two is another HIV-1 M group template used as the internal quantitation standard. A known amount of template two is added to the test sample, before proceeding with RT-PCR and CLIP. The two templates are simultaneously co-amplified, using an RT-PCR procedure. For the CLIP sequencing, template one is sequenced using P1, a CY 5.0 labeled forward primer, and P2, a Cy 5.5 labeled reverse primer. Template two is sequenced using P3, a Cy 7.0 labeled forward primer, and P4, an unlabelled reverse primer. The template one fragment defined by the primers P1 and P2 is the same size, and approximately the same composition and sequence, as the template two fragment defined by the primers P3 and P4. The forward primers P1 and P3 are identical in length. However, P1 and P3 differ from each other only by the three nucleotides at the 3' end of the oligonucleotide primer. Thus, the two forward primers P1 and P3, although identical in length, and similar in AT content and Tm, only function as sequencing primers for their designated templates, i.e. template one and two respectively. Similarly, the reverse primers P2 and P4 are identical in length, but again differ in the three nucleotides at the 3' end of the oligonucleotide primer. Once again, this results in similar overall AT content and Tm, but the reverse primers P2 and P4 are template specific. Both templates are amplified and sequenced in one CLIP reaction, using AmpliTaq FS polymerase, terminating dideoxynucleoside triphosphates and non-terminating deoxynucleoside triphosphates, and cycled through multiple thermal cycles. The reaction products are analyzed using a Visible Genetics Long Read Tower system, to determine both the sequence and the quantity of template one, using template two as the internal standard for quantitation.

45

50

55

Claims

5

10

15

20

25

30

35

40

45

50

55

5

- 17 -

CLAIMS

10

1. A method for simultaneous sequencing and quantitation of a target
2 nucleic acid analyte in a sample, comprising the steps of:

3 (a) processing the sample using a single set of reagents through a
4 plurality of thermocycles, in which said single set of reagents includes at least one
5 labeled reagent for labeling the target nucleic acid or a product derived from the target
6 nucleic acid, to obtain a mixture of labeled polynucleotides fragments derived from the
7 target nucleic acid which are used for the determination of both sequence information
8 about the target nucleic acid and the amount of target nucleic acid present in the sample,
9 said processing being carried out within a quantitative regime;

10 (b) separating the labeled nucleic acid sequencing fragments in the
11 modified sample on the basis of size and detecting the label associated with the separated
12 polynucleotide fragments;

13 (c) evaluating the positions of the separated nucleic acid fragments to
14 obtain information about the sequence of the target nucleic acid analyte; and

15 (d) evaluating the intensity of a signal derived from the label
16 associated with one or more of the separated polynucleotide fragments to determine the
17 quantity of the target nucleic acid analyte in the sample.

35

1 2. The method of claim 1, further comprising the step of amplifying
target nucleic acid in the sample prior to step (a).

40

1 3. The method of claim 1, wherein terminated sequencing fragments
2 are used for the determination of both sequence information about the target nucleic acid
3 and the amount of target nucleic acid present in the sample.

45

1 4. The method of claim 1, wherein a full-length amplification
2 product is used for determination of the amount of target nucleic acid present in the
3 sample.

50

55

5

- 18 -

10

15

1 5. The method of claim 4, wherein the sample is processed in two
2 parallel replicate reactions to produce both full-length product and terminated
3 polynucleotide sequencing fragments, said two reactions including a first reaction which
4 is stopped after a first number of thermal cycles such that the production of full-length
5 product is within a quantitative regime, and a second reaction which is stopped after a
6 second number of thermal cycles greater than the first number of thermal cycles such that
7 the production of sequencing fragments is within a quantitative regime.

20

25

1 6. The method of claim 4, wherein the sample is processed in a
2 single reaction and a first aliquot of the single reaction is removed after a first number of
3 thermal cycles such that the production of full-length product is within a quantitative
4 regime, said full length-product in the first aliquot being used for determination of the
5 amount of target nucleic acid in the sample, and wherein the sample is further processed
6 after the removal of the first aliquot for an additional number of thermal cycles such that
7 production of sequencing fragments is within a quantitative regime.

30

35

1 7. The method of claim 4, wherein an internal polynucleotide
2 standard is added to the sample in a known amount and coprocessed in the same reaction
3 vessel to produce a detectable reference product, and wherein the intensity of a signal
4 derived from the reference product is compared to the intensity of the signal derived from
5 the label associated with the separated fragments to determine the quantity of the target
6 nucleic acid analyte in the sample.

40

1 8. The method of claim 7, further comprising the step of amplifying
2 target nucleic acid in the sample prior to step (a).

45

1 9. The method of claim 7, wherein the target nucleic acid is an RNA
2 target, and wherein the method further comprises the step of reverse transcribing the
3 RNA target to produce a cDNA template prior to step (a).

50

1 10. The method of claim 1, wherein an internal polynucleotide
2 standard is added to the sample in a known amount and coprocessed in the same reaction

55

5

- 19 -

10

3 vessel to produce a detectable reference product, and wherein the intensity of a signal
4 derived from the reference product is compared to the intensity of the signal derived from
5 the label associated with the separated fragments to determine the quantity of the target
6 nucleic acid analyte in the sample.

15

1 11. The method of claim 10, further comprising the step of amplifying
2 target nucleic acid in the sample prior to step (a).

20

1 12. The method of claim 10, wherein the target nucleic acid is an RNA
2 target, and wherein the method further comprises the step of reverse transcribing the
3 RNA target to produce a cDNA template prior to step (a).

25

1 13. The method of claim 10, wherein terminated sequencing fragments
2 are used for the determination of both sequence information about the target nucleic acid
3 and the amount of target nucleic acid present in the sample.

30

1 14. The method of claim 1, wherein both a full-length product and
2 terminated sequencing fragments are used for the determination of the amount of target
3 nucleic acid present in the sample.

35

1 15. The method of claim 1, wherein the target nucleic acid is an RNA
2 target, and wherein the method further comprises the step of reverse transcribing the
3 RNA target to produce a cDNA template prior to step (a).

40

45

1 16. The method of claim 15, wherein the target nucleic acid analyte is
2 HIV-1, and wherein the sample is processed using primers flanking a region of interest
3 within the HIV-1 genome.

50

1 17. The method of claim 16, wherein an internal polynucleotide
2 standard is added to the sample in a known amount and coprocessed in the same reaction
3 vessel to produce a detectable reference product, and wherein the intensity of a signal

55

5

- 20 -

10

4 derived from the reference product is compared to the intensity of the signal derived from
5 the label associated with the separated fragments to determine the quantity of the target
6 nucleic acid analyte in the sample.

15

1 18 A kit for sequence analysis and quantitation of a target nucleic
2 acid in a sample, comprising:

20

3 (a) at least one primer pair flanking a region of analytical interest
4 within the target nucleic acid, wherein at least one member of the primer pair is labeled
5 with a detectable label;

6

6 (b) a thermostable template-dependent DNA polymerase,
7 (c) feedstock solutions and buffers for performing a thermally-cycled
8 primer extension reaction, and

25

9 (d) calibration information specific to the reagents within the kit, said
10 calibration information providing the information to correlate the amount of the target
11 nucleic acid analyte in the sample with the amount of polynucleotide product produced
12 through the use of the kit.

30

1 19. The kit of claim 18, wherein the target nucleic acid is an RNA,
2 further comprising a reverse transcriptase.

35

1 20. A kit for sequence analysis and quantitation of a target nucleic
2 acid in a sample, comprising:

40

3 (a) at least one primer pair flanking a region of analytical interest
4 within the target nucleic acid, wherein at least one member of the primer pair is labeled
5 with a first detectable label;

45

6 (b) a thermostable template-dependent DNA polymerase,
7 (c) feedstock solutions and buffers for performing a thermally-cycled
8 primer extension reaction,
9 (d) a reference polynucleotide, and

50

55

5

- 21 -

10

10 (e) at least one reference primer pair flanking a region of the reference
11 polynucleotide, wherein at least one member of the reference primer pair is labeled with
12 a second detectable distinguishable from the first detectable label.

10

15

1 21. The kit of claim 20, wherein the target nucleic acid is an RNA.
2 further comprising a reverse transcriptase.

20

1 22. The kit of claim 20, further comprising a pair of amplification
2 primers, wherein the amplification primers are effective for amplification of both the
3 target nucleic acid and the reference polynucleotide.

25

1 23. The kit of claim 22, wherein the amplification primers produce
2 amplification products of equal length from the target nucleic acid and the reference
3 polynucleotide.

30

35

40

45

50

55




FIG. 1




FIG. 2

2/10




FIG. 3

3/10




FIG. 4

4/10




FIG. 5-A

5/10




FIG. 5-B

6/10





FIG. 6

7/10



8/10




FIG. 8

9/10




FIG. 9

10/10




FIG. 1O

INTERNATIONAL SEARCH REPORT

International application No
PCT/US00/12822

A. CLASSIFICATION OF SUBJECT MATTER		
IPC(7) C12P 19/34, C12M 1/34 US CL 435.91.1, 91.2, 287.2 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S. 435.6, 91.1, 91.2, 183, 287.2, 810, 536.23.1, 24.3, 24.33, 25.3		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,E	US 6,083,763 A (BALCH) 04 July 2000 (04.07.00), see entire document.	1-23
Y	US 5,876,919 A (KLEYN et al.) 02 March 1999 (02.03.99), see entire document.	1-23
Y	US 5,629,314 A (GASKIN) 13 May 1997 (13.05.97), see entire document.	1-23
Y	US 5,834,189 A (STEVENS et al.) 10 November 1998 (10.11.98), see entire document.	1-23
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents *A* document defining the general state of the art which is not considered to be of particular relevance *B* earlier document published on or after the international filing date *C* document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified) *D* document referring to an oral disclosure, use, exhibition or other means *E* document published prior to the international filing date but later than the priority date claimed		
F later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *G* document of particular relevance, the claimed invention cannot be considered novel, or cannot be considered to involve an inventive step when the document is taken alone *H* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *I* document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report	
11 JULY 2000	07 SEP 2000	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer: <i>myra</i> BRADLEY L. SISSON Telephone No. (703) 308-0196	

Form PCTCSA 210 (second sheet) (July 1998) *

INTERNATIONAL SEARCH REPORT

International application No
PCT/US00/12822

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used)

EAST

Search terms: polymerase chain reaction, pcr, sequencing, quantitative